A consortium led by former boss David Gao has filed an all-cash $3.9 billion offer for Nasdaq-listed China Biologic Products, topping an existing bid by Citic Capital Holdings as the battle to take the plasma treatment provider private heats up anew.
¬ Haymarket Media Limited. All rights reserved.
